Yes, partnerships! The whole company has been restructured for a year and half for partnerships. We got rid of our research people. If we get an new CEO, their job will be to make partnership deals. We got enough data from two Covid years to figure out the benefits of Leronlimab in different indications. We are enticing enough right now for a partnership, and best case would be two companies fighting over an indication.

There are no easy ways around FDA/BP; once Novavax finally got approval on their vaccine their stock went from $70 to $10! Going it alone, even with great data and an approval would be tough. Time to join BP.